Drugs / OPB-111001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02042885 | Jan 2014 → Feb 2015 | breast cancer, cervical squamous cell carcinoma, endometrial cancer, ovarian cancer +2 | Otsuka Novel Products GmbH | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPB-111001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02042885 ↗ |
| Route | Oral | “OPB-111001, orally, once weekly” NCT02042885 ↗ |